...
首页> 外文期刊>Toxicon: An International Journal Devoted to the Exchange of Knowledge on the Poisons Derived from Animals, Plants and Microorganisms >Acute and repeated dose toxicity studies of recombinant saxatilin, a disintegrin from the Korean snake (Gloydius saxatilis)
【24h】

Acute and repeated dose toxicity studies of recombinant saxatilin, a disintegrin from the Korean snake (Gloydius saxatilis)

机译:重组saxatilin的急性和反复剂量毒性研究,这是一种来自韩国蛇的解整合素

获取原文
获取原文并翻译 | 示例
           

摘要

To examine the toxicological effect of saxatilin, a disintegrin isolated from the venom of a Korean snake (Gloydius saxatilis), recombinant saxatilin was highly expressed as a biologically active form in Pichia pastoris, and was successfully purified to homogeneity from the culture broth supernatant. The molecular and biological properties of the recombinant protein were the same as those of its natural form. Plasma half-life of the protein in rat was determined to 13.8 min. The maximum tolerated dose of the recombinant saxatilin was examined in ICR mice. The determined LD50 values were 400 and 600 mg/kg of the body weight of a male and female mouse, respectively. To investigate the repeated dose toxicity of saxatilin in mice, the test item was intravenously administered to groups of ICR mice every day for 4 weeks. We observed a decrease in locomotor activity, piloerection, and crouching in clinical findings, a decrease of red blood cells (RBCs) in hematology, and hyperplasia of the spleen in histology related to administration of the test item. These results suggest that the target organ of intravenous administration of the test item is the spleen. The no adverse effect level (NOAEL) in this test for both males and females is considered to be 3 mg/kg. Our results also indicate that recombinant saxatilin is nontoxic at an administration dose with an anti-platelet effect, and might be a potential anti-adhesion therapeutic agent for thrombosis, cancer, restenosis, cataract, and osteoporosis. (c) 2007 Elsevier Ltd. All rights reserved.
机译:为了检查从朝鲜蛇毒(Gloydius saxatilis)分离出的一种整合素saxatilin的毒理作用,重组saxatilin在巴斯德毕赤酵母中具有高生物活性形式,并已从培养液上清液中成功纯化至同质。重组蛋白的分子和生物学特性与其天然形式相同。确定该蛋白在大鼠中的血浆半衰期为13.8分钟。在ICR小鼠中检查了重组萨沙替林的最大耐受剂量。确定的LD50值分别为雄性和雌性小鼠的体重的400和600 mg / kg。为了研究沙沙替林在小鼠中的重复剂量毒性,每天将试验项目静脉内施用给ICR小鼠组,持续4周。我们在临床发现中观察到运动活动,竖毛和蹲伏的减少,血液学中红细胞(RBC)的减少,以及与给药该测试项目相关的组织学中脾脏的增生。这些结果表明,静脉内施用测试物的靶器官是脾脏。在该测试中,男性和女性的无副作用水平(NOAEL)被认为是3 mg / kg。我们的结果还表明,重组萨沙汀在给药剂量时无毒,具有抗血小板作用,并且可能是血栓形成,癌症,再狭窄,白内障和骨质疏松症的潜在抗粘连治疗剂。 (c)2007 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号